First-in-Class Assets & Promising New Targets

Repare is building a portfolio of assets addressing both novel and well-characterized targets with the potential to precisely treat identified patient populations with genetically defined cancers.  Behind the portfolio of assets rapidly advancing towards development candidate selection, a growing pipeline of novel and industry-validated targets continues to be generated by Repare’s proprietary discovery platform.


For partnership and business development contact us at: